TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX) has received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $40.67.

Several equities analysts have recently issued reports on the stock. TD Cowen started coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target for the company. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group increased their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. Finally, HC Wainwright upped their price target on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock opened at $27.67 on Tuesday. TG Therapeutics has a 1-year low of $12.84 and a 1-year high of $36.84. The company has a 50 day moving average of $31.55 and a 200-day moving average of $25.52. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a market cap of $4.31 billion, a PE ratio of -276.67 and a beta of 2.24.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. During the same period in the previous year, the firm posted $0.73 EPS. The business’s quarterly revenue was down 49.4% compared to the same quarter last year. As a group, equities research analysts forecast that TG Therapeutics will post 0.17 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Sean A. Power sold 11,337 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $30.29, for a total value of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares in the company, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,358 shares of company stock valued at $781,497 in the last three months. Company insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. NBC Securities Inc. increased its stake in TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 485 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of TG Therapeutics in the 2nd quarter worth about $35,000. Blue Trust Inc. increased its position in shares of TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 849 shares during the last quarter. ORG Wealth Partners LLC purchased a new position in shares of TG Therapeutics during the 3rd quarter valued at about $53,000. Finally, Values First Advisors Inc. bought a new stake in TG Therapeutics in the 3rd quarter worth approximately $58,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.